Table 3.

Univariable (UVA) and multivariable (MVA) Cox regression model for prediction of early biochemical recurrence for clinical benefit cohort

		UVA		MVA
GC Subset	Variable	HR (95% CI)	P value	HR (95% CI)	P value
Low/intermediate risk	CAPRA-S	1.5 (0.5–2.7)	0.345	1.4 (0.0–1265.0)	0.449
	Treated vs not treated	4.0 (0.0–75.0)	0.456	1.3 (0.0–84.3)	0.926
High risk	CAPRA-S	1.2 (0.8–1.8)	0.430	1.5 (0.9–2.3)	0.093
	Treated vs not treated	0.2 (0.0–0.8)	0.030*	0.1 (0.0–0.6)	0.013*

CAPRA-S Cancer of the Prostate Risk Assessment score, GC genomic classifiers, HR hazard ratio, MVA multivariable analysis, PSA prostate-specific antigen, UVA univariable analysis, 95% CI 95% confidence interval, *significant p-value